Now I have sufficient calibration. Let me write the final consolidated review.

---

## Summary

This paper proposes using synthetic tumors—inserted into healthy CT volumes via a modeling-based generator—as a validation set for model selection in liver tumor segmentation, and introduces a "continual learning" framework that trains on dynamically generated synthetic tumors. The core idea (synthetic data *for validation* rather than only for training) is genuinely novel and practically motivated. However, the experimental design conflates multiple variables, making it impossible to cleanly attribute the headline gains to synthetic validation specifically. The "continual learning" framing is a mislabeling of standard online data augmentation. These problems are structural and require major revision.

## Strengths

- **Novel idea of using synthetic data for validation, not just training.** Prior work extensively uses synthetic data for training augmentation; the paper's proposal to use it specifically for checkpoint selection is a well-motivated departure. The motivation (Sections 1 and 5.1) that a small real validation set fails to detect overfitting—shown concretely in Figure 2 where the test curve declines after epoch ~1500 while the real validation curve stays flat—is convincingly demonstrated.

- **Controlled within-training comparison shows synthetic validation helps for synthetic-trained models.** Table 2 reports that for models *trained on synthetic tumors*, switching from real validation (best@real) to synthetic validation (best@synt) raises DSC from 33.4%→34.5% (in-domain) and 33.3%→35.4% (out-domain). This is a meaningful, if modest, controlled comparison that holds the training paradigm fixed.

- **Large improvement in tiny tumor detection.** Sensitivity for tumors with radius <5mm improves from 33.1% to 55.4% (in-domain) and 33.9% to 52.3% (out-domain) under the full proposed framework (Figure 5). This is clinically significant and demonstrates real value in the overall pipeline.

- **Transparent tumor generation pipeline.** The four-step generator (shape, texture, location, post-processing) is grounded in LI-RADS clinical criteria and described in sufficient methodological detail (Section 3.2) to enable reproduction.

- **Statistical reporting with 10 runs and 95% CIs.** The paper reports results averaged over ten runs with confidence intervals (Table 2), providing more statistical rigor than is common in many medical imaging papers.

## Weaknesses

### Major

1. **Headline results conflate training and validation changes.** The abstract and introduction foreground a DSC improvement from 26.7% to 34.5% (e.g., "the DSC score of liver tumor segmentation improves from 26.7% to 34.5%"). This compares *trained on real tumors, best@real* vs. *trained on synthetic tumors, best@synt*—changing both the training data and the validation data simultaneously. The large gain is driven primarily by switching to synthetic **training** (which has effectively unlimited data), not by the validation strategy. The paper's central claim in the title ("synthetic data as validation") is not isolated from this confound. The abstract should not present a conflated comparison as headline evidence for the validation claim.

2. **Validation set size is confounded with synthetic vs. real.** The real validation set (cohort 2) has 5 CT volumes; the synthetic validation set (cohort 5) has 50 CT volumes. The paper attributes improved checkpoint selection to the *synthetic nature* of the data, but the effect could simply be larger sample size producing more reliable performance estimates. The paper acknowledges this issue (Section 5.2, lines 145-153) but does not control for it. A simple control—downsampling the synthetic validation set to match real validation size—is not provided. This confound weakens every comparison that crosses the real/synthetic validation boundary.

3. **"Continual learning" framing is misleading.** The paper describes its dynamic training setup as a "continual learning framework" (Section 3.1, claim #3 in the introduction), but the actual experiment trains a single model for 6000 epochs with no task boundaries, no sequential task ordering, no evaluation of catastrophic forgetting, and no replay or regularization mechanisms. The method is simply standard online data augmentation (generating new tumor instances on the fly). The Van de Ven & Tolias (2019) paper the paper itself cites defines continual learning around sequentially encountered non-i.i.d. tasks, which is not what is implemented. This framing inflates the paper's claimed novelty and should be dropped.

4. **Real-training baseline uses no data augmentation.** The real-trained model uses only 25 CT volumes with no mention of standard augmentation (flips, rotations, intensity shifts, etc.), while the synthetic training paradigm generates unlimited variations. This is an apples-to-oranges comparison. Any method that increases effective dataset size could trivially outperform a small unaugmented baseline. A fair comparison would apply standard data augmentation to the real training set, or at minimum discuss why it was omitted.

### Minor

5. **For real-trained models, synthetic validation provides negligible benefit.** Within the real-training paradigm, switching from real validation to synthetic validation yields only 26.7%→27.0% (in-domain) and 31.1%→32.0% (out-domain). Both differences are well within overlapping 95% CIs. This substantially limits the generality of the "synthetic data as validation" claim—the benefit appears contingent on also using synthetic training data.

6. **The paper's two claimed contributions (synthetic training and synthetic validation) are not disentangled.** The experimental design bundles both into the same comparisons. The paper would be substantially stronger if it made two clean claims: (i) synthetic training improves over real training (controlling for data size and augmentation), and (ii) synthetic validation improves over real validation (controlling for validation set size). Currently, neither claim is convincingly isolated.

### Trivial

7. **The tumor generator parameters (σ_d, μ, σ_g for deformation and noise) are referenced with symbols but not given concrete values in the main text.** While the code is provided as supplementary, the main paper should specify key numerical parameters for reproducibility.

## Nice-to-Haves

- For synthetic-trained models, the gain from synthetic validation (33.4→34.5 in-domain, 33.3→35.4 out-domain) would benefit from formal statistical significance testing rather than just CI overlap inspection.
- Comparing synthetic validation to other model-selection strategies (e.g., k-fold cross-validation, early stopping on training loss) would contextualize the benefit.

## Removed Points

- **"The method soundness is questionable" (Harsh Critic's broader methodological concerns).** These are wrapped into the retained weaknesses above. Fully removed as redundant.
- **"Missing appendix" and "references missing."** The parser strips appendices; these exist in the original submission. Removed per hard rules.
- **"Reproducibility nitpicks about undisclosed hyperparameters beyond those already described."** The paper gives the main generator pipeline details and provides code. Removed per hard rules.
- **"Weakness about unfair comparison if asymmetry favors baseline."** The criticism that the synthetic-trained baseline has more data is legitimate and retained as weakness #4; the broader complaint about "unfair comparison" is subsumed.
- **Strength Finder's "rigorous experimental design."** The experiments do report CIs and 10 runs, which is good. But the design confounds are significant. I keep the specific practice (CI reporting) as a strength but remove the generic "rigorous experimental design" tag.

## Novel Insights

None beyond the paper's own contributions. The idea of using synthetic data for validation specifically (rather than only for training) is the paper's core insight, but the reviewers' analyses do not reveal additional novel perspectives beyond what the paper itself articulates.

## Suggestions

1. **Cleanly separate the two contributions.** Run (a) synthetic-trained model with real validation vs. synthetic validation (controlling validation set size, e.g., 5 vs. 5 volumes), and (b) real-trained model with heavy data augmentation vs. synthetic-trained model (controlling data diversity). Present these as two independent experiments.
2. **Drop the "continual learning" framing entirely.** The method is online data augmentation with dynamic generation. Label it as such.
3. **Downsample the synthetic validation set to match the real validation size** (5 volumes) and rerun the comparison. If the benefit persists, the claim that synthetic *composition* (not just size) helps is supported. If it vanishes, the paper's main claim needs significant revision.
4. **Add standard data augmentation (random flips, rotations, intensity jitter) to the real-training baseline** to make the training comparison fair.
5. **Rephrase the abstract** so the headline numbers compare apples to apples (e.g., trained@synt + best@real vs. trained@synt + best@synt, or trained@real + best@real vs. trained@real + best@synt + data augmentation).

## Score and Decision

**Calibration process:**

Round 1 bracketing: Three queries for "liver tumor segmentation synthetic data medical imaging" returned weak anchors (avg 2.3–3.0), middle anchors (avg 4.5–6.0), and strong anchors (avg 7.7–9.0). The paper is clearly above the weak anchors' quality (flawed methods, withdrawn) and clearly below the strong anchors (oral/spotlight papers with major contributions). Initial bracket: (4, 6.5).

Round 2 narrowing: Two targeted queries returned anchors in the 4–6 range. Key comparisons:
- **DSPart** (5.25 avg, Reject): Synthetic dataset for part segmentation. Similar technical scope, comparable execution quality. The current paper has a more novel idea (validation vs. dataset creation) but weaker experimental isolation.
- **GenDataAgent** (6.25 avg, Accept): On-the-fly synthetic data augmentation. Better-executed experiments with clearer isolation. The current paper is weaker.
- **Selective LoRA** (5.5 avg, Reject): Synthetic data for urban-scene segmentation. Comparable execution quality but less confounded design.
- **CoinGAN** (4.5 avg, Reject): Weakly supervised medical lesion segmentation. The current paper has more comprehensive experiments.

The paper's experimental confounds (especially the failure to isolate synthetic validation from training changes and validation set size) place it below the cleaner experimental designs of GenDataAgent, SegGen, and Selective LoRA. Its novel idea is a genuine asset, but the evidence does not adequately support the central claim in its present form.

**Final assessment:** The paper addresses a worthwhile question and has a genuinely novel angle, but the experimental design does not convincingly isolate the claimed contribution. Major revision with better-controlled experiments is needed before the paper can substantiate its central thesis.

**Score: 4.5**

**Decision: Reject**

MY FINAL SCORE: <score>4.5</score>
MY FINAL DECISION: <decision>Reject</decision>